Alzamend Neuro Inc (ALZN) News

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the...

Form 5 - Annual statement of changes in beneficial ownership of securities

Alzamend Neuro Announces Initial Closing of Private Placement

Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and...

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

Form 8-K/A - Current report: [Amend]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 8-K - Current report

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the...